Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2023-12-15 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) filing from the company Olix. It details the finalization of a private placement of convertible bonds (2nd series), including the total amount issued and the payment date. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments.
2023-12-15 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (OliX) regarding the 'Acquisition of Convertible Bonds before Maturity'. It details the specific bond series, the amount acquired, the reason for acquisition (early redemption due to contract termination), and the method of disposal (cancellation). This type of disclosure regarding changes to debt instruments and capital structure falls under the 'Capital/Financing Update' category.
2023-12-14 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or the meeting results, but rather serves as a formal regulatory announcement of the record date. Given it is a standard regulatory notification regarding corporate governance and meeting preparation, it falls under the general regulatory filing category.
2023-12-13 Korean
투자판단관련주요경영사항(GalNAc-asiRNA 기술을 이용한 Collaboration and License Agreement 관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the receipt of a milestone payment from a licensing agreement with Jiangsu Hansoh Pharmaceuticals. Since this is a specific regulatory disclosure of a material event (milestone payment receipt) rather than a report publication announcement, a financial report, or a general press release, it falls under the 'Regulatory Filings' category.
2023-12-07 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service and Korea Exchange, specifically detailing the decision to issue convertible bonds (전환사채권 발행결정). This type of regulatory filing in the Korean market is a formal disclosure of capital structure changes and financing activities. It fits the 'Capital/Financing Update' (CAP) category as it details the issuance of debt instruments convertible into equity, including terms, interest rates, and use of proceeds.
2023-12-07 Korean
기타경영사항(자율공시)(제1회차 전환우선주 전환가액 조정)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Conversion Price Adjustment' for convertible preferred shares. This type of disclosure relates to changes in the company's capital structure and potential future share issuance resulting from the conversion of debt/preferred instruments. Since it specifically details the adjustment of conversion prices and the resulting change in the number of convertible shares, it falls under the category of capital and financing updates.
2023-11-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.